

References

1. Taieb J, Le Malicot K, Shi Q, et al. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer. *J Natl Cancer Inst.* 2017;109(5).
2. Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. *Ann Oncol.* 2016;27(8):1386-1422.
3. Walter T, Hawkins NS, Pollock RF, Colaone F, Shergill S, Ross PJ. Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer. *J Cancer Res Clin Oncol.* 2020;146(10):2575-2587.
4. Su G-L, Wang Y-Y, Wang J-C, Liu H. A meta-analysis comparing regorafenib with TAS-102 for treating refractory metastatic colorectal cancer. *J Int Med Res.* 2020;48(7):0300060520926408.
5. Huemer F, Piringer G, Schlintl V, et al. Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy. *Cancers (Basel).* 2020;12(10):2812.
6. Unseld M, Fischöder S, Jachs M, et al. Different Toxicity Profiles Predict Third Line Treatment Efficacy in Metastatic Colorectal Cancer Patients. *J Clin Med.* 2020;9(6).
7. European Medicines Agency (EMA). Stivarga Summary of Product Characteristics (SmPC). https://www.ema.europa.eu/en/documents/product-information/stivarga-epar-product-information_en.pdf. Published 2018. Accessed 24 February, 2021.
8. Swissmedic. Lonsurf. <https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/authorisations/new-medicines/lonsurf-filmtabletten-tipiracilum.html>. Published 2017. Accessed 24 February, 2021.
9. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Ver. 1.2021. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Published 2020. Accessed 24 February, 2021.
10. Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer. *N Engl J Med.* 2015;372(20):1909-1919.
11. Cicero G, Addeo R, De Luca R, et al. TAS-102 in metastatic colorectal cancer (mCRC): efficacy, tolerability, and quality of life in heavily pretreated elderly patients: a real-life study. *Drugs Context.* 2020;9.
12. Wallander M, Rolander B, Åvall-Lundqvist E, Elander NO. Real world aspects of palliative trifluridine plus tiperacil (TAS-102) in refractory metastatic colorectal cancer. *J Gastrointest Oncol.* 2020;11(4):616-625.
13. Ogata M, Kotaka M, Ogata T, et al. Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan. *PLoS One.* 2020;15(6):e0234314-e0234314.
14. Tabernero J, Argiles G, Sobrero AF, et al. Effect of trifluridine/tipiracil in patients treated in RECURSE by prognostic factors at baseline: an exploratory analysis. *ESMO Open.* 2020;5(4):e000752.
15. Cheung WY, Kavan P, Dolley A. Quality of life in a real-world study of patients with metastatic colorectal cancer treated with trifluridine/tipiracil. *Curr Oncol.* 2020;27(5):e451-e458.

16. Tabernero J, Van Cutsem E, Ohtsu A, et al. QTWiST analysis of the RECURSE trial of trifluridine/tipiracil in metastatic colorectal cancer. *ESMO Open*. 2017;2(5):e000284.
17. Patel AK, Barghout V, Yenikomshian MA, et al. Real-World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib. *Oncologist*. 2020;25(1):e75-e84.